Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into an exclusive distribution agreement (“Agreement”) with Breathalyser Sales & Service Pty Ltd., (“Breathalyser SSP”) for Australia, New Zealand and the Pacific Islands for its BreathLogix autonomous (unmanned) alcohol breathalyzer devices (Figures 1 and 2). This marks Cannabix’s first international distribution and sales agreement for its BreathLogix alcohol screening product line. BreathLogix rapidly checks breath alcohol, simultaneously takes a photo of the user, alerts managers in real-time to help avoid injury and damage due to alcohol impairment.
Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use, offering well established alcohol product lines like Draeger and AlcoMeasure for the Australian market with regional offices in Perth, Melbourne and Brisbane. Breathalyser SSP has clients in a range of sectors including mining, oil and gas, industrial, trucking, warehousing and technology.
Highlights
- Cannabix enters first international distribution and sales agreement for the BreathLogix autonomous (unmanned) alcohol breathalyzer product line.
- BreathLogix will be targeted to mining, oil and gas, industrial, trucking, warehousing industries.
- The exclusive distribution agreement is for an initial 2-year term and covers the territories of Australia, New Zealand and the Pacific Islands.
- The Australian market for employer pre-access wall mounted alcohol screening devices is mature and well developed.
- The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its BreathLogix alcohol technology with first distribution agreements announced for Canada, Australia, New Zealand and the Pacific Islands. The Company is pursuing distribution partners in the United States.
Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is actively transitioning from research and development to delivering innovative new technologies in breath testing to the market. We are very pleased be partnering with Breathalyser Sales & Service Pty Ltd of Australia, who have many years of experience with various industries deploying pre-access alcohol testing to improve employee safety.”
Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia’s oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, autonomous employee alcohol screening is a major segment of our business, and we look forward to representing the BreathLogix product line.”
Figure 1. BreathLogix Alcohol Screening Devices
Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
BreathLogix Alcohol Screening Devices
BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.
BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company’s products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/84ff6a85-6e60-4915-adea-db2d305d5a26
https://www.globenewswire.com/NewsRoom/AttachmentNg/b1d7bc42-f84d-4391-b555-6738d45f043f
